MeiraGTx Q3 net loss $50.5M; enters ophthalmology collaboration with Lilly for $75M upfront

MeiraGTx Holdings plc

2025-Q3 EPS reported -$1.61 vs consensus -$0.50 ▼ miss (-222.1%)

Collaboration with Lilly: upfront $75M, eligible for >$400M milestones and tiered royalties on ocular programs.
Cash $14.8M at Sept 30; with Lilly $75M and Hologen $150M expected, runway into H2 2027 covers $75M debt due Aug 2026.
Net loss $50.5M ($0.62/share) vs $39.3M ($0.55) YoY; service revenue fell to $0.4M from $10.9M as J&J PPQ substantially completed.
AAV-hAQP1 Phase 2 enrollment target end of 2025; positive data could support BLA filing early 2027.
AAV-GAD Phase 3 for Parkinson's expected to initiate in coming months; RMAT designation granted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.